Merck (MRK) Corporate presentation summary

Strategic vision and growth drivers

• Focus on value creation through integrated capabilities in life science, healthcare, and electronics, leveraging expertise in biology, chemistry, physics, data, and AI.

• Portfolio development targets high-growth drivers, integrated workflow solutions, platformed capabilities, and innovation via M&A and in-licensing.

• Resource allocation prioritizes businesses with the highest value and market attractiveness, aiming for leadership in integrated solutions.

• Mid-term guidance targets mid-single-digit organic sales growth and a step-up to ~30% EBITDA pre margin.

Business segment performance and outlook

• Life Science: Strong growth in Process Solutions (~10% CAGR), Advanced Solutions (mid- to high-single-digit), and Discovery Solutions (low-single-digit), with a diversified, global customer base.

• Healthcare: Rare Diseases drive double-digit growth, with new launches and global expansion; Fertility & Endocrinology and Cardiometabolic maintain leadership and steady growth.

• Electronics: Semiconductor Solutions is the main growth engine (7–11% CAGR), driven by AI, advanced nodes, and 3D densification, with a resilient, vertically integrated business model.

Key initiatives and investments

• Announced all-cash acquisition of Bio-Techne for $11.3bn, expected to be accretive to sales and margins, with significant cost synergies and EPS accretion by year 3.

• Ongoing investments in R&D, external innovation, and pipeline expansion, especially in rare diseases and next-generation ADCs.

• Capital allocation aligns with long-term ambition, targeting 25% of sales for R&D in the mid-term.